AstraZeneca’s antibiotic Zavicefta met primary endpoints in phase III trial for treatment of hospital-acquired pneumonia
AstraZeneca today announced positive results from the Phase III REPROVE trial for Zavicefta (ceftazidime-avibactam), a new combination antibiotic for the treatment of a broad range of serious Gram-negative bacterial infections in hospitalised patients.